
News|Articles|March 14, 2024
Plastic Debris in Carotid Plaque Linked to CV Events: Daily Dose
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
Last week, we reported on findings from a study published in The New England Journal of Medicine that examined whether microplastics and nanoplastics (MNPs) are detectable within atherosclerotic plaque and whether the burden of MNPs is associated with cardiovascular disease (CVD).
The study
Investigators conducted the prospective, multicenter, observational study of patients with asymptomatic carotid artery disease undergoing carotid endarterectomy. The primary endpoint was a composite of myocardial infarction (MI), stroke, and death from any cause.
Researchers enrolled 304 participants, of whom 257 completed a mean follow-up of 33.7 months. They detected polyethylene in carotid artery plaque of 58.4% of patients (n=150; mean level, 21.7 μg/mL of plaque), and “measurable amounts” of polyvinyl chloride in plaque of 12.1% of patients (n=31; mean level, 5.2 μg/mL of plaque).
The findings
Results showed participants in whom MNPs were detected within the atheroma were at a higher risk of the primary endpoint event (composite of MI, stroke, all-cause death) than those in whom no MNPs were detected (HR 4.53, 95% CI 2.00-10.27; P < .001).
Authors' comment
"In this study, patients with carotid artery plaque in which MNPs were detected had a higher risk of a composite of myocardial infarction, stroke, or death from any cause at 34 months of follow-up than those in whom MNPs were not detected."
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
ACOG Releases New Guidance on HIV Screening and Prevention
2
2026 Dyslipidemia Guideline Expands Statin Eligibility to 21.5 Million More US Adults
3
From Amyloid Clearance to Daytime Function: Why Sleep Quality Matters for Brain Health
4
FDA Approves First Oral PCSK9 Inhibitor to Reduce LDL-C in Adults With Hypercholesterolemia
5





























































































































































